Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mayte Coiras, Juan Ambrosioni, Francisco Cervantes, José M. Miró & José Alcamí. (2017) Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. Expert Opinion on Drug Safety 16:5, pages 547-559.
Read now
Read now
Articles from other publishers (23)
Süreyya YİĞİT KAYA. (2023) Recurrent Herpes Infection in Two Cases with Chronic Myeloid Leukemia Using DasatinibDasatinib Kullanan Kronik Myeloid Lösemi Tanılı İki Olguda Tekrarlayan Herpes Enfeksiyonu. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi 10:1, pages 65-66.
Crossref
Crossref
Elizabeth C. Lorenz, LaTonya J. Hickson, Pascale Khairallah, Bijan Najafi & Cassie C. Kennedy. (2023) Cellular Senescence and Frailty in Transplantation. Current Transplantation Reports 10:2, pages 51-59.
Crossref
Crossref
Joseph Kauer, Melanie Märklin, Martin Pflügler, Sebastian Hörner, Clemens Hinterleitner, Claudia Tandler, Gundram Jung, Helmut R. Salih & Jonas S. Heitmann. (2022) BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of Cancer Research and Clinical Oncology 148:10, pages 2759-2771.
Crossref
Crossref
Eriko Uchida, Shoji Saito, Daisuke Morita, Eri Okura, Koichi Hirabayashi, Miyuki Tanaka, Hideyuki Nakazawa, Akane Minagawa & Yozo Nakazawa. (2022) Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment. Pediatric Blood & Cancer 69:8.
Crossref
Crossref
Hannah Hsu, Vincent Seah, Deborah Marriott & John Moore. (2022) Enterococcus cecorum infective endocarditis in a patient with chronic myeloid leukaemia and cirrhosis. Pathology 54:4, pages 495-497.
Crossref
Crossref
Alexandra Rayson, Maya Boudiffa, Maneeha Naveed, Jon Griffin, Enrico Dall’Ara & Ilaria Bellantuono. (2022) Geroprotectors and Skeletal Health: Beyond the Headlines. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Maria Zulfiqar, Christine Menias, Anup Shetty, Daniel R. Ludwig, Sana Saif Ur Rehman, Hilary Orlowski & Vincent Mellnick. (2022) Imaging Spectrum of Infections in the Setting of Immunotherapy and Molecular Targeted Therapy. Current Problems in Diagnostic Radiology 51:1, pages 86-97.
Crossref
Crossref
Samir Morsli & Ilaria Bellantuono. (2021) The use of geroprotectors to prevent multimorbidity: Opportunities and challenges. Mechanisms of Ageing and Development 193, pages 111391.
Crossref
Crossref
Lorena Vigón, Sara Rodríguez-Mora, Alejandro Luna, Virginia Sandonís, Elena Mateos, Guiomar Bautista, Juan Luis Steegmann, Nuria Climent, Montserrat Plana, Pilar Pérez-Romero, Fernando de Ory, José Alcamí, Valentín García-Gutierrez, Vicente Planelles, María Rosa López-Huertas & Mayte Coiras. (2020) Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology 182, pages 114203.
Crossref
Crossref
Ahmed M. Abdalhadi, Awni Alshurafa, Mohammed Alkhatib, Mohamed Abou Kamar & Mohamed A. Yassin. (2020) Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome. Case Reports in Oncology 13:2, pages 569-577.
Crossref
Crossref
Katie Bechman, James B Galloway & Kevin L Winthrop. (2019) Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Current Fungal Infection Reports 13:4, pages 229-243.
Crossref
Crossref
Sarah Atkins & Fiona He. (2019) Chemotherapy and Beyond. Infectious Disease Clinics of North America 33:2, pages 289-309.
Crossref
Crossref
Amber C. King, Jeremy J. Pappacena, Martin S. Tallman, Jae H. Park & Mark B. Geyer. (2019) Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia Research 79, pages 27-33.
Crossref
Crossref
Mercedes Bermejo, Juan Ambrosioni, Guiomar Bautista, Núria Climent, Elena Mateos, Cristina Rovira, Sara Rodríguez-Mora, María Rosa López-Huertas, Valentín García-Gutiérrez, Juan Luis Steegmann, Rafael Duarte, Francisco Cervantes, Montserrat Plana, José M. Miró, José Alcamí & Mayte Coiras. (2018) Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology 156, pages 248-264.
Crossref
Crossref
Karen Seiter, Dominick Latremouille-Viau, Annie Guerin, Briana Ndife, Karen Habucky, Derek H. Tang, Irina Pivneva, Patrick Gagnon-Sanschagrin & George J. Joseph. (2018) Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Advances in Therapy 35:10, pages 1671-1685.
Crossref
Crossref
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi & J.M. Aguado. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 24, pages S53-S70.
Crossref
Crossref
Bettina M. Knoll & K. Seiter. (2018) Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature. Infection 46:3, pages 409-418.
Crossref
Crossref
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann & R E Clark. (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30:8, pages 1648-1671.
Crossref
Crossref
Mercedes Bermejo, María Rosa López-Huertas, Javier García-Pérez, Núria Climent, Benjamin Descours, Juan Ambrosioni, Elena Mateos, Sara Rodríguez-Mora, Lucía Rus-Bercial, Monsef Benkirane, José M. Miró, Montserrat Plana, José Alcamí & Mayte Coiras. (2016) Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochemical Pharmacology 106, pages 30-45.
Crossref
Crossref
Naif I. AlJohani, Simon Carette & Jeffrey H. Lipton. (2015) Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report. Journal of Medical Case Reports 9:1.
Crossref
Crossref
Mark ReinwaldTobias BochWolf-Karsten HofmannDieter Buchheidt. (2016) Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights 10s3, pages BMI.S22430.
Crossref
Crossref
Hung Chang, Yu-Shin Hung & Wen-Chi Chou. (2014) Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment. International Journal of Infectious Diseases 25, pages 165-167.
Crossref
Crossref
Elisabetta Abruzzese, Massimo Breccia & Roberto Latagliata. (2013) Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). BioDrugs 28:1, pages 17-26.
Crossref
Crossref